Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of First Quarter 2020
PharmaShots’ Key Highlights of First Quarter 2020
The first quarter of 2020 includes big news regarding global companies. The highlight of the quarter is the acquisition of QIAGEN by ThermoFisher for ~$11.5B, Danaher's acquisition of the biopharma business of GE Life Sciences in an all-cash transaction for ~$21.4B. Numerous alliances are there which include Fosun's agreement with BioNTech to develop and commercialize…
April 8, 2020
Insights+: The US FDA New Drug Approvals in February 2020
Insights+: The US FDA New Drug Approvals in February 2020
The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 13 novel products so far in 2020, including 10 in Feb and 3 in Jan…
March 27, 2020
Insights+: Breakthrough Therapy Designation by the US FDA in 2019
Insights+: Breakthrough Therapy Designation by the US FDA in 2019
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…
March 13, 2020
Insights+ Key Biosimilars Events of February 2020
Insights+ Key Biosimilars Events of February 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients The Korean firm, Celltrion's Remsima also showed some updates in fields of approval and…
March 6, 2020
Insights+: COVID-19 Healthcare News Monthly Updates - February 2020
Insights+: COVID-19 Healthcare News Monthly Updates – February 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named 'SARS-CoV-2'(severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named 'Coronavirus Disease 2019'(COVID-19). The outbreak of the respiratory disease was first detected in Wuhan…
February 28, 2020
Insights+ Key Biosimilars Events of January 2020
Insights+ Key Biosimilars Events of January 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the US Our team at PharmaShots has summarized key…
February 14, 2020
Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020
Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…
February 7, 2020
Insights+: COVID-19 Healthcare News Monthly Updates - March 2020
Insights+: COVID-19 Healthcare News Monthly Updates – March 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
January 31, 2020
PharmaShots' Key Highlights of Fourth Quarter 2019
PharmaShots’ Key Highlights of Fourth Quarter 2019
1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date - Oct 01, 2019 Product - Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019,…
January 24, 2020
Load more